New hope for adults with rare leukemia: drug combo shows promise in early trial
NCT ID NCT05157971
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial is testing whether adding the drug venetoclax to a chemotherapy regimen originally designed for children can be safe and effective for adults aged 18-54 with a specific, aggressive form of B-cell acute lymphoblastic leukemia (Ph-like ALL). The study will enroll 24 participants to find the best dose and watch for side effects. If successful, this approach could offer a more targeted treatment option for this hard-to-treat leukemia.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- venetoclax
- What this could lead to
- If this works, it could lead to a more effective and tolerable treatment for adults with a hard-to-treat form of acute lymphoblastic leukemia.
- What could go wrong
- This is a very early phase 1 trial with only 24 participants, so safety and dosing are still being figured out. The combination may cause serious side effects, and it's too soon to know if it will improve outcomes.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for B-ACUTE LYMPHOBLASTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
City of Hope Medical Center
Duarte, California, 91010, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can donor immune cells be engineered to fight blood cancer?
- Can a Chemo-Antibody combo beat a tough leukemia?
- Personalized chemo dosing may boost leukemia remission in kids
- Could a simple drug tame the dangerous side effects of CAR-T cancer therapy?
- Targeted drug aims to clear hidden leukemia before transplant
- Supercharged immune cells take aim at cancer and viruses in one shot